Lamivudine; Raltegravir Potassium Patent Expiration
Lamivudine; Raltegravir Potassium is Used for managing HIV-1 infection. It was first introduced by Merck Sharp And Dohme Corp
Lamivudine; Raltegravir Potassium Patents
Given below is the list of patents protecting Lamivudine; Raltegravir Potassium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dutrebis |
US7754731 (Pediatric) | Potassium salt of an HIV integrase inhibitor | Sep 11, 2029 | Merck Sharp Dohme |
| Dutrebis | US7754731 | Potassium salt of an HIV integrase inhibitor | Mar 11, 2029 | Merck Sharp Dohme |
| Dutrebis |
US7169780 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 03, 2024
(Expired) | Merck Sharp Dohme |
| Dutrebis | US7169780 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 03, 2023
(Expired) | Merck Sharp Dohme |
| Dutrebis | US7820660 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 25, 2023
(Expired) | Merck Sharp Dohme |
| Dutrebis |
US7217713 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Merck Sharp Dohme |
| Dutrebis |
US7435734 (Pediatric) | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr 21, 2023
(Expired) | Merck Sharp Dohme |
| Dutrebis | US7217713 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Merck Sharp Dohme |
| Dutrebis | US7435734 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct 21, 2022
(Expired) | Merck Sharp Dohme |
Lamivudine; Raltegravir Potassium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List